Vensana Capital

Moxe Health Corporation develops a clinical data clearinghouse that enables the efficient bi-directional exchange of clinical, analytic, and administrative data among health systems, health plans, and healthcare technology vendors. The company offers solutions that automate chart retrieval and the release of information, transitioning health systems from manual processes to a fully electronic, auditable method of record management. Moxe’s platform facilitates access to essential data for risk adjustment, quality improvement, and care management programs, supporting health plans and providers in the shift to value-based care. Through its Substrate integration platform and Convergence framework, Moxe ensures that relevant patient information is integrated directly into clinician workflows within electronic medical records. Founded in 2012 and based in Madison, Wisconsin, Moxe Health aims to enhance the connectivity and functionality of existing healthcare data systems while maintaining compliance with HIPAA regulations.

Apella is a technology company that brings modern engineering to improve surgery. It was founded in 2020 and is headquartered in San Francisco, California.

Cleerly is a healthcare company focused on improving the prevention of heart attacks through innovative digital care pathways. It aims to establish a new standard for coronary artery disease by combining advanced clinical science with cutting-edge artificial intelligence. Cleerly's platform offers a non-invasive approach that quantifies and characterizes plaque buildup in coronary arteries, enhancing the understanding of cardiovascular health. By providing actionable clinical insights, the company enables healthcare providers to better identify at-risk patients and implement early treatment strategies. Ultimately, Cleerly's data-driven solutions aspire to deliver significant value to the healthcare system while improving heart health outcomes for individuals susceptible to heart attacks.

GPB Scientific, LLC is a biotechnology company based in Richmond, Virginia, that specializes in developing a liquid biopsy platform aimed at isolating viable circulating tumor cells from blood samples. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating and enriching rare tumor cells while removing red blood cells and normal white blood cells. GPB Scientific markets its innovative technology to life sciences companies and research institutions, supported by a substantial portfolio of patents related to microchip technology for cell capture and enrichment. Established in 2002, GPB Scientific continues to advance its contributions to cancer diagnostics and research.

Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.

Spyglass Ophthalmics, Inc. is a company focused on developing ophthalmic therapeutic devices aimed at enhancing vision and eye care for patients. Founded in 2019 and based in Mission Viejo, California, Spyglass addresses unmet needs in areas such as cataract treatment, lens replacement, and other chronic ophthalmic conditions. By creating innovative devices, the company seeks to provide patients with quality eye treatment that is also affordable.

Relievant Medsystems, Inc. is a medical device company focused on addressing chronic axial low back pain through a minimally invasive procedure known as Intracept. This innovative treatment specifically targets the basivertebral nerve, utilizing radio-frequency energy delivered through a small access tube into the vertebral body to ablate the nerve. The procedure is performed under real-time fluoroscopic guidance, ensuring precision and safety. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic solutions that significantly improve the quality of life for patients suffering from vertebrogenic low back pain.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

GPB Scientific, LLC is a biotechnology company based in Richmond, Virginia, that specializes in developing a liquid biopsy platform aimed at isolating viable circulating tumor cells from blood samples. The company offers a desktop fluidic system that processes whole blood through a disposable microchip, effectively separating and enriching rare tumor cells while removing red blood cells and normal white blood cells. GPB Scientific markets its innovative technology to life sciences companies and research institutions, supported by a substantial portfolio of patents related to microchip technology for cell capture and enrichment. Established in 2002, GPB Scientific continues to advance its contributions to cancer diagnostics and research.

Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Vesper Medical, Inc. is a medical device company established in 2016 and based in Wayne, Pennsylvania. The company focuses on developing minimally invasive peripheral vascular products specifically designed for treating deep venous disease. Its flagship offering, the Vesper DUO Venous Stent System, features a unique combination of strength and flexibility that addresses the complex anatomical challenges of venous stenting, particularly in the iliac and femoral veins. Vesper Medical aims to provide safe, effective, and user-friendly solutions for both patients and healthcare providers, enhancing the treatment of deep venous conditions.